Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J.

J Clin Oncol. 2010 Jan 1;28(1):21-8. doi: 10.1200/JCO.2009.23.8584. Epub 2009 Nov 16.

PMID:
19917865
2.

Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.

Jansen JF, Schöder H, Lee NY, Wang Y, Pfister DG, Fury MG, Stambuk HE, Humm JL, Koutcher JA, Shukla-Dave A.

Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1403-10. doi: 10.1016/j.ijrobp.2009.07.009. Epub 2009 Nov 10.

3.
4.

Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging.

Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G, Chalian A, Poptani H.

AJNR Am J Neuroradiol. 2010 Feb;31(2):262-8. doi: 10.3174/ajnr.A1817. Epub 2009 Oct 1.

5.

Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.

Koch WM, Ridge JA, Forastiere A, Manola J.

Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):851-8. doi: 10.1001/archoto.2009.123. Erratum in: Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1136.

6.

Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas.

Li X, Di B, Shang Y, Zhou Y, Cheng J, He Z.

Eur J Surg Oncol. 2009 Dec;35(12):1348-53. doi: 10.1016/j.ejso.2009.06.010. Epub 2009 Jul 18.

PMID:
19616915
7.

Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.

Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, Gribbestad IS.

J Magn Reson Imaging. 2009 Jun;29(6):1300-7. doi: 10.1002/jmri.21778.

PMID:
19472387
8.

Functional imaging of head and neck cancers.

Emonts P, Bourgeois P, Lemort M, Flamen P.

Curr Opin Oncol. 2009 May;21(3):212-7. Review.

PMID:
19370804
9.

Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases.

Shukla-Dave A, Lee N, Stambuk H, Wang Y, Huang W, Thaler HT, Patel SG, Shah JP, Koutcher JA.

BMC Med Phys. 2009 Apr 7;9:4. doi: 10.1186/1756-6649-9-4.

10.

Head and neck cancer emerging strategies: advances and new challenges.

Awada A, de Castro G Jr.

Curr Opin Oncol. 2009 May;21(3):191-3. doi: 10.1097/CCO.0b013e32832a6e05. No abstract available.

PMID:
19346942
11.

Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer.

Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, Intenzo CM, Keane W.

Head Neck. 2009 Feb;31(2):195-201. doi: 10.1002/hed.20942.

PMID:
19107945
12.

Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study.

Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T, Bradford C, Mukherji SK, Eisbruch A.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1287-90. doi: 10.1016/j.ijrobp.2008.08.024.

13.

Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes.

Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, See LC, Yen TC.

Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):764-71. doi: 10.1016/j.ijrobp.2008.05.004. Epub 2008 Oct 2.

PMID:
18835509
14.

FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma.

Suzuki H, Hasegawa Y, Terada A, Hyodo I, Nakashima T, Nishio M, Tamaki T.

Oral Oncol. 2009 Jul;45(7):569-73. doi: 10.1016/j.oraloncology.2008.07.009. Epub 2008 Sep 18.

PMID:
18804407
15.

Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.

Vaupel P.

Oncologist. 2008;13 Suppl 3:21-6. doi: 10.1634/theoncologist.13-S3-21. Review.

16.

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML.

J Natl Cancer Inst. 2008 Feb 20;100(4):261-9. doi: 10.1093/jnci/djn011. Epub 2008 Feb 12.

PMID:
18270337
17.

Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.

Klem ML, Mechalakos JG, Wolden SL, Zelefsky MJ, Singh B, Kraus D, Shaha A, Shah J, Pfister DG, Lee NY.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1100-7. Epub 2007 Nov 5.

PMID:
17980501
18.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group.

N Engl J Med. 2007 Oct 25;357(17):1705-15.

19.

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

Jackson A, O'Connor JP, Parker GJ, Jayson GC.

Clin Cancer Res. 2007 Jun 15;13(12):3449-59. Review.

20.

Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.

Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68. Epub 2007 May 9.

PMID:
17493769

Supplemental Content

Support Center